Background: The DynamX Novolimus-Eluting Coronary Bioadaptor System
(DynamX
Announcements
Open Access
Original Research
Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data
Stefan Verheye1,*, Mathias Vrolix2, Matteo Montorfano3, Francesco Giannini4, Francesco Bedogni5, Christophe Dubois6, Bernard De Bruyne7, Ricardo A. Costa8, Daniel Chamié8, José Ribamar Costa Jr8, Alexandre Abizaid8, Antonio Colombo9,10
Show Less
1
Interventional Cardiology, ZNA Cardiovascular Center Middelheim, 2020 Antwerp, Belgium
2
Department of Cardiology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium
3
Interventional Cardiology Unit, San Raffaele Scientific Institute, 20132 Milan, Italy
4
Interventional Cardiology Unit, GVM Care & Research, Maria Cecilia Hospital, 48010 Cotignola (RA), Italy
5
Department of Cardiology, IRCCS Policlinico San Donato, 20097 San Donato Milanese-Milan, Italy
6
Department of Cardiovascular Medicine, Universitaire Ziekenhuizen Leuven, 3000 Leuven, Belgium
7
Cardiovascular Center, OLV Hospital, 9300 Aalst, Belgium
8
Cardiovascular Research Center, 04012-070 São Paulo, Brazil
9
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele-Milan, Italy
10
Humanitas Clinical and Research Center IRCCS, 20089 Rozzano-Milan, Italy
*Correspondence: stefan.verheye@gmail.com (Stefan Verheye)
Rev. Cardiovasc. Med. 2023, 24(8), 221;
https://doi.org/10.31083/j.rcm2408221
Submitted: 24 February 2023 | Revised: 4 April 2023 | Accepted: 4 May 2023 | Published: 1 August 2023
(This article belongs to the Special Issue New Advances in Drug Eluting Stents)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Keywords
coronary artery disease
bioadaptor
drug-eluting stent
novolimus
target lesion failure
vessel motion
pulsatility
vasomotion
thrombosis
Funding
Elixir Medical Corporation
Figures
Fig. 1.